Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis.

Front Oncol · 2025 · PMC11883363 · PMID 40052124

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a suggestive trendno p-value reported

In those who did, there was a suggestive trend for median OS to be longer in patients expressing higher levels of PD-L1; however, there was a borderline statistically significant difference in PFS curves according to the duration of index nivolumab treatment (p = 0.046).

also in 52 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.